| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10328029 | CYCLE | Pharmaceutical composition |
Jan, 2035
(10 years from now) | |
Nityr is owned by Cycle.
Nityr contains Nitisinone.
Nityr has a total of 1 drug patent out of which 0 drug patents have expired.
Nityr was authorised for market use on 26 July, 2017.
Nityr is available in tablet;oral dosage forms.
Nityr can be used as treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine.
The generics of Nityr are possible to be released after 05 January, 2035.
Drugs and Companies using NITISINONE ingredient
Market Authorisation Date: 26 July, 2017
Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
Dosage: TABLET;ORAL
More Information on Dosage
NITYR family patents
